Tutogen Medical and Regeneration Technologies Enter Strategic Tissue Sourcing Relationship
November 06 2006 - 8:00AM
PR Newswire (US)
ALACHUA, Fla., Nov. 6 /PRNewswire-FirstCall/ -- Tutogen Medical,
Inc. (AMEX:TTG), a leading manufacturer of sterile biological
implant products made from human (allograft) and animal (xenograft)
tissue, and Regeneration Technologies, Inc. (RTI) (NASDAQ:RTIX),
the Florida-based processor of orthopedic, cardiovascular and other
biologic implants, announced today that the companies have entered
into mutual sourcing agreements. Under the terms of the new
agreements, RTI will have first right of refusal to all soft tissue
used in sports medicine surgeries recovered by Tutogen's recovery
partners. Tutogen, in turn, will have first right of refusal to all
dermis, fascia and pericardium recovered by RTI Donor Services
agencies. The agreements are in effect immediately. The companies
will also explore other areas of future cooperation on sourcing
activities to maximize each gift of donated tissue and to offer
patients the best biologic alternatives. "We are excited about this
new sourcing agreement with Tutogen Medical," said Brian K.
Hutchison, RTI's chairman, president and CEO. "The soft tissue we
receive from Tutogen will help us meet the high demand for RTI's
sterilized sports medicine implants. In turn, Tutogen will be
better able to meet the demand for their dental, urological, hernia
and aesthetics implants." Guy Mayer, CEO of Tutogen, said: "This
new agreement is significant in assuring full use of these donated
tissues for our patients and in assuring our ability to meet the
expanding demands of our partners for our entry into the important
hernia repair and aesthetics markets." "This is a very positive
development for all involved," continued Mr. Mayer. "The generosity
of our tissue donors will be treated with the greatest of care and
respect in helping as many people in need as possible to achieve
enhanced medical outcomes and improved quality of life. Both
organizations are dedicated to accomplishing that mission." About
Regeneration Technologies, Inc. RTI processes allograft and
xenograft tissue into shaped implants for use in orthopedic,
cardiovascular and other surgeries with a commitment to science,
safety and innovation. RTI also holds the patents on BioCleanse(R),
the only proven tissue sterilization process validated to eliminate
viruses, bacteria, fungi and spores from tissue without impacting
the structural or biomechanical integrity of the tissue. The
company has distributed more than half a million allograft implants
sterilized with the BioCleanse process with zero incidence of
infection. RTI is accredited by the American Association of Tissue
Banks and was named a 2004 Technology Pioneer by the World Economic
Forum. Except for historical information, any statements made in
this press release about the company's anticipated financial
results, future operational results, regulatory approvals or
changes to the company's agreements with its distributors are
forward-looking statements subject to risks and uncertainties, such
as those described in the company's public filings on file with the
Securities and Exchange Commission. Actual results may differ
materially from anticipated results reflected in these
forward-looking statements. Copies of the company's SEC filings may
be obtained by contacting the company or the SEC or by visiting
RTI's web site at http://www.rtix.com/ or the SEC's web site at
http://www.sec.gov/. About Tutogen Medical, Inc. Tutogen Medical,
Inc. manufactures sterile biological implant products made from
human (allograft) and animal (xenograft) tissue. Tutogen utilizes
its Tutoplast Process(R) of tissue preservation and viral
inactivation to manufacture and deliver sterile bio-implants used
in spinal/trauma, urology, dental, ophthalmology, and general
surgery procedures. The Company's Tutoplast(R) products are sold
and distributed worldwide by Zimmer Spine and Zimmer Dental,
subsidiaries of Zimmer Holdings, Inc., Davol Inc. subsidiary of
C.R. Bard Inc., the Mentor Corporation (Mentor), Coloplast Corp.,
IOP, Inc. and through independent distributors internationally. For
more information, visit the Company's Web site at
http://www.tutogen.com/. Forward-Looking Statement Disclaimer: This
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements typically are identified by use of terms
such as "may," "will," "should," "plan," "expect," "anticipate,"
"estimate," and similar words, although some forward-looking
statements are expressed differently. Forward-looking statements
are based on management's current expectations and are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those set forth or implied by
forward-looking statements. These and other risks are identified in
the Company's filings with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K for the fiscal
year ended September 30, 2005, as amended. All information in this
press release is as of the date hereof, and the Company undertakes
no duty to update this information unless required by law.
Contacts: L. Robert Johnston, Jr. Chief Financial Officer Tutogen
Medical, Inc. 386-462-0402 Lytham Partners, LLC Joe Diaz Joe Dorame
Robert Blum 602-889-9700 DATASOURCE: Tutogen Medical, Inc. CONTACT:
L. Robert Johnston, Jr., Chief Financial Officer of Tutogen
Medical, Inc., +1-386-462-0402, ; or Joe Diaz, Joe Dorame, or
Robert Blum, all of Lytham Partners, LLC, +1-602-889-9700, for
Tutogen Medical, Inc. Web site: http://www.tutogen.com/
http://www.rtix.com/
Copyright
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Jul 2023 to Jul 2024